{
    "organizations": [],
    "uuid": "5d96ec38f0411d6d5b6fd0e9722a2edcbdd338c3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-akebia-therapeutics-gives-update-o/brief-akebia-therapeutics-gives-update-on-vadadustat-development-program-idUSASB0C552",
    "ord_in_thread": 0,
    "title": "BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Akebia Therapeutics Inc:\n* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM\n* AKEBIA THERAPEUTICS INC - TARGETS FULL ENROLLMENT FOR INNO(2)VATE AND PRO(2)TECT BY END OF 2018\n* AKEBIA THERAPEUTICS INC - CONFIRMS EXPECTATION OF TOP-LINE RESULTS FOR INNO(2)VATE & PRO(2)TECT IN 2019, SUBJECT TO ACCRUAL OF MACE EVENTS\n* AKEBIA THERAPEUTICS INC - PARTNER MITSUBISHI TANABE PHARMA CORP INITIATES PHASE 3 NDD-CKD AND DD-CKD PROGRAM IN JAPAN Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-12T20:13:00.000+02:00",
    "crawled": "2018-02-13T15:28:21.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "akebia",
        "therapeutic",
        "inc",
        "akebia",
        "therapeutic",
        "provides",
        "update",
        "vadadustat",
        "development",
        "program",
        "akebia",
        "therapeutic",
        "inc",
        "target",
        "full",
        "enrollment",
        "inno",
        "vate",
        "pro",
        "tect",
        "end",
        "akebia",
        "therapeutic",
        "inc",
        "confirms",
        "expectation",
        "result",
        "inno",
        "vate",
        "pro",
        "tect",
        "subject",
        "accrual",
        "mace",
        "event",
        "akebia",
        "therapeutic",
        "inc",
        "partner",
        "mitsubishi",
        "tanabe",
        "pharma",
        "corp",
        "initiate",
        "phase",
        "program",
        "japan",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}